Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.

ABSTRACT:

Background

Graft-versus-host disease (GvHD) is the main life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). Thirty to 80% of GvHD patients do not respond to first-line treatment and a second-line treatment is not universally established. Based on their immunomodulatory properties, mesenchymal stromal cells (MSC) have been proposed for the prevention and the treatment of GvHD in patients undergoing HSCT. Unfortunately, previous studies reported conflicting results regarding the prophylactic and therapeutic effects of MSC for GvHD. Consequently, we carried out a meta-analysis to clarify whether MSC administration can improve the dismal outcome of these patients.

Methods

We carried out a systematic review and selected studies (2004-2019)

SUBMITTER: Morata-Tarifa C 

PROVIDER: S-EPMC7027118 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature